Targets › TOP2A
24 programs from 18 companies in 67 trials: 32 Phase 2, 21 Phase 1, 13 Phase 3, 1 Phase 4; Oncology, Hematology, Infectious disease; next expected readout Dec 2026.
Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand. May play a role in regulating the period length of BMAL1 transcriptional oscillation (By similarity). (UniProt, P11388)
Open in Phaseline: the race on TOP2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital JP Garrahan | ABVD Combination chemotherapy: Doxorubicin (topoisomerase II inhibitor), Bleomycin (DNA damagin | TOP2A, CHEK1 | Phase 4 | Pediatric Hodgkin's Disease | Oct 2027 |
| European Organisation for Research and Treatment of Cancer - EORTC | Epirubicin (EpiADM) Anthracycline; topoisomerase II inhibitor | TOP2A | Phase 3 | Retroperitoneal Sarcoma | Apr 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | daunorubicin DNA topoisomerase II alpha inhibitor | TOP2A | Phase 3 | AML; CEBPA Double Mutation; Acute Leukemia of Ambiguous Lineage | Jun 2027 |
| Children's Oncology Group | Daunorubicin Hydrochloride DNA topoisomerase II alpha inhibitor | TOP2A | Phase 3 | Acute Myeloid Leukemia | Jun 2027 |
| IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | epirubicin hydrochloride Anthracycline; intercalates into DNA and inhibits topoisomerase II | TOP2A | Phase 3 | Breast Cancer | Dec 2027 |
| CSPC ZhongQi Pharmaceutical Technology | Mitoxantrone DNA topoisomerase II alpha inhibitor | TOP2A | Phase 3 | Peripheral T Cell Lymphoma; Acute Myeloid Leukaemia; B-cell Acute Lymphoblastic Leukemia; Soft Tissue Sarcoma … | Dec 2027 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | Dexrazoxane DNA topoisomerase II inhibitor | TOP2A, TOP2B | Phase 3 | DLBCL - Diffuse Large B Cell Lymphoma | Dec 2028 |
| European Organisation for Research and Treatment of Cancer - EORTC | ABVD regimen Combination of doxorubicin, bleomycin, vinblastine, and dacarbazine - multi-modal chemothe | Tubulin, TOP2A, MYC | Phase 3 | Lymphoma | – |
| European Organisation for Research and Treatment of Cancer - EORTC | BEACOPP regimen Combination of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbaz | TOP2A, Tubulin | Phase 3 | Lymphoma | – |
| European Organisation for Research and Treatment of Cancer - EORTC | doxorubicin hydrochloride DNA topoisomerase II alpha inhibitor | TOP2A | Phase 3 | Lymphoma | – |
| National Cancer Institute (NCI) | Daunorubicin Hydrochloride DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Acute Myeloid Leukemia | Feb 2027 |
| National Cancer Institute (NCI) | Doxorubicin Hydrochloride DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Fallopian Tube High Grade Serous Adenocarcinoma; Metastatic Dedifferentiated Liposarcoma; Ann Arbor Stage III Non-Hodgkin Lymphoma | May 2027 |
| ImmunityBio | Aldoxorubicin DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Pancreatic Cancer | May 2027 |
| Fred Hutchinson Cancer Center | Idarubicin DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Acute Leukemia of Ambiguous Lineage; Acute Myeloid Leukemia | Jun 2027 |
| M.D. Anderson Cancer Center | Dexrazoxane Hydrochloride DNA topoisomerase II inhibitor | TOP2A, TOP2B | Phase 2 | Acute Myeloid Leukemia | Dec 2027 |
| M.D. Anderson Cancer Center | Idarubicin DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Acute Biphenotypic Leukemia; Acute Myeloid Leukemia | Dec 2027 |
| Navy General Hospital, Beijing | idarubicin DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Primary Central Nervous System Lymphoma | Dec 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | idarubicin DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Hepatic Cancer; Lung Cancer | Dec 2028 |
| University Hospital, Angers | Vosaroxin Topoisomerase II inhibitor (quinolone derivative) | TOP2A | Phase 2 | Acute Myeloid Leukemia (AML) | Jan 2032 |
| M.D. Anderson Cancer Center | Etoposide phosphate DNA topoisomerase II alpha inhibitor | TOP2A | Phase 2 | Lymphoma | Jan 2034 |
| CNS Pharmaceuticals | Berubicin DNA topoisomerase II inhibitor | TOP2A, TOP2B | Phase 2 | Glioblastoma Multiforme, Adult | – |
| Princess Maxima Center for Pediatric Oncology | Vyxeos®/CPX-351 Liposomal daunorubicin and cytarabine combination | TOP2A | Phase 1 | Relapsed Pediatric AML | Dec 2026 |
| City of Hope Medical Center | Doxorubicin Hydrochloride DNA topoisomerase II alpha inhibitor | TOP2A | Phase 1 | FIGO Stage IVA Ovarian Cancer; AIDS-Related Burkitt Lymphoma | Jan 2027 |
| SkinJect | Doxorubicin-containing MNA Topoisomerase II inhibitor delivered via dissolvable microneedle array | TOP2A | Phase 1 | Basal Cell Carcinoma | – |
Acute Myeloid Leukemia (8) Lymphoma (7) Peripheral T Cell Lymphoma (4) Non Hodgkin Lymphoma (4) Acute Leukemia of Ambiguous Lineage (2) AML (2) Relapse Acute Myeloid Leukemia (2) Acute Biphenotypic Leukemia (2) Primary Central Nervous System Lymphoma (2) CEBPA Double Mutation (1) Fallopian Tube High Grade Serous Adenocarcinoma (1) Metastatic Dedifferentiated Liposarcoma (1)
mixed (13), small molecule (9), antibody (1)
European Organisation for Research and Treatment of Cancer - EORTC (4) M.D. Anderson Cancer Center (3) National Cancer Institute (NCI) (2) Fred Hutchinson Cancer Center (1) Institute of Hematology & Blood Diseases Hospital, China (1) SkinJect (1) CNS Pharmaceuticals (1) CSPC ZhongQi Pharmaceutical Technology (1) University Hospital, Angers (1) Navy General Hospital, Beijing (1) ImmunityBio (1) Children's Oncology Group (1) City of Hope Medical Center (1) Second Affiliated Hospital of Guangzhou Medical University (1) Stichting Hemato-Oncologie voor Volwassenen Nederland (1) IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1) Princess Maxima Center for Pediatric Oncology (1) Hospital JP Garrahan (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.